SCHEMBL19657271

SCHEMBL19657271

CC(C)c1cnc(C(=O)N2CCOCC2)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.46
ALDH1A1 P00352 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
FKBP1A P62942 2/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MAPT P10636 2/20 0.45
PKM P14618 2/20 0.45
TSHR P16473 2/20 0.45
HTT P42858 1/20 0.45
HSP90AA1 P07900 3/20 0.44
HSP90AB1 P08238 2/20 0.44
KDM4E B2RXH2 1/20 0.44
PIK3CD O00329 1/20 0.43
PIK3R2 O00459 1/20 0.43
PIK3CA P42336 1/20 0.43
PIK3CB P42338 1/20 0.43
PIK3CG P48736 1/20 0.43
PIK3R5 Q8WYR1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24869249 0.88 KMT2A (0.47) HPGDALDH1A1KMT2ANPC1RAB9A
SCHEMBL19651862 0.85 HSP90AA1 (0.45) HPGDALDH1A1KMT2AL3MBTL1FKBP1A
SCHEMBL24869257 0.83 SPR (0.40) HPGD
SCHEMBL19657270 0.82 HPGD (0.52) HPGDKMT2ANPC1RAB9AMAPT
SCHEMBL24869247 0.82 HCRTR1 (0.37) ALDH1A1KMT2ANPC1RAB9AMAPT
SCHEMBL15765229 0.80 HPGD (0.51) HPGDL3MBTL1NPC1RAB9AMAPT
SCHEMBL19105521 0.77 ALDH1A1 (0.48) HPGDALDH1A1KMT2AL3MBTL1FKBP1A
SCHEMBL24869264 0.76 KDM5A (0.34) ALDH1A1TSHRGAAMAPK1
SCHEMBL12546101 0.76 MAPT (0.57) HPGDALDH1A1KMT2AL3MBTL1FKBP1A
SCHEMBL24869265 0.74 SPR (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183009-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2019-01-22 US disclosed
US-20170340605-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10183009-B2 Therapeutic compounds and uses thereof BRD4, BRDT, BRPF3 HPGD 1603/4885ALDH1A1 2006/4885KMT2A 126/4885
US-20170340605-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRPF3 HPGD 1603/4885ALDH1A1 2006/4885KMT2A 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.